{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:08:12Z","timestamp":1773274092660,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsthoracicsurgery.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Annals of Thoracic Surgery"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.athoracsur.2015.12.004","type":"journal-article","created":{"date-parts":[[2016,1,19]],"date-time":"2016-01-19T23:45:15Z","timestamp":1453247115000},"page":"2407-2416","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives"],"prefix":"10.1016","volume":"101","author":[{"given":"Michael G.","family":"Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony S.","family":"Fargnoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew P.","family":"Kendle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger J.","family":"Hajjar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.athoracsur.2015.12.004_bib1","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib2","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.1171242","article-title":"Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy","volume":"326","author":"Cartier","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib3","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib6","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1161\/01.CIR.82.6.2217","article-title":"Expression of recombinant genes in myocardium in\u00a0vivo after direct injection of DNA","volume":"82","author":"Lin","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib7","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/S1010-7940(02)00174-4","article-title":"Acceptance of gene therapy by the heart surgery patient","volume":"21","author":"Bonatti","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib8","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1161\/CIRCRESAHA.109.200386","article-title":"Human studies of angiogenic gene therapy","volume":"105","author":"Gupta","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib9","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00395-011-0200-1","article-title":"Therapeutic neovascularization for coronary disease: current state and future prospects","volume":"106","author":"Lassaletta","year":"2011","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.CIR.100.5.468","article-title":"Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease","volume":"100","author":"Rosengart","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib12","first-page":"373","article-title":"Gene therapy of coronary artery disease with phvegf165\u2014early outcome","volume":"59","author":"Ko\u0142sut","year":"2003","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib13","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1253\/circj.CJ-09-0594","article-title":"Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting\u2014a multicenter phase I and safety study","volume":"74","author":"Kilian","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib14","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.jtcvs.2007.09.073","article-title":"Concomitant treatment with oral L-arginine improves the efficacy of surgical angiogenesis in patients with severe diffuse coronary artery disease: the Endothelial Modulation in Angiogenic Therapy randomized controlled trial","volume":"135","author":"Ruel","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib15","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/gt.2012.87","article-title":"Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study","volume":"20","author":"Kim","year":"2013","journal-title":"Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib16","article-title":"Phase II trial of the E2F decoy in coronary bypass grafting (abstract)","author":"Grube","year":"2001","journal-title":"Presented at the American Heart Association Annual Meeting, Anaheim, CA"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib17","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.294.19.2446","article-title":"Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib18","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.98.25.2800","article-title":"Gene therapy for\u00a0myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia","volume":"98","author":"Losordo","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib19","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0003-4975(99)00807-3","article-title":"Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease","volume":"68","author":"Symes","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib20","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1161\/01.CIR.102.9.965","article-title":"Left ventricular electromechanical mapping to assess efficacy of phVEGF(165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia","volume":"102","author":"Vale","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1540-8183.2005.04026.x","article-title":"Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in no-option patients","volume":"18","author":"Reilly","year":"2005","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","article-title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment","volume":"13","author":"Stewart","year":"2006","journal-title":"Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib23","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1590\/S0102-76382010000300006","article-title":"VEGF gene therapy for angiogenesis in refractory angina: phase I\/II clinical trial","volume":"25","author":"Kalil","year":"2010","journal-title":"Rev Bras Cir Cardiovasc"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1540-8183.2001.tb00367.x","article-title":"Therapeutic angiogenesis in critical limb and myocardial ischemia","volume":"14","author":"Vale","year":"2001","journal-title":"J\u00a0Interv Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib25","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/01.CIR.0000015982.70785.B7","article-title":"Phase 1\/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia","volume":"105","author":"Losordo","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris: a randomized double-blind placebo-controlled study: the Euroinject One trial","volume":"45","author":"Kastrup","year":"2005","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib27","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib28","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/eurheartj\/ehl117","article-title":"Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease","volume":"27","author":"Ripa","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib29","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib30","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1161\/hc1102.105595","article-title":"Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris","volume":"105","author":"Grines","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0735-1097(03)00988-4","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina","volume":"42","author":"Grines","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","article-title":"Effects of Ad5FGF- 4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials","volume":"50","author":"Henry","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/10430340050016003","article-title":"Catheter-mediated vascular endothelial growth factor gene transfer to human coronary arteries after angioplasty","volume":"11","author":"Laitinen","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2012.08.018","article-title":"Gene targeting in ischemic heart disease and failure: translational and clinical studies","volume":"85","author":"Eckhouse","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib35","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1089\/hum.2013.2517","article-title":"Gene therapy delivery systems for enhancing viral and nonviral vectors for cardiac diseases: current concepts and future applications","volume":"24","author":"Katz","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib37","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ahj.2010.11.023","article-title":"Intramyocardial plasmid-encoding human vascular endothelial growth factor A165\/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD)","volume":"161","author":"Kuku\u0142a","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib38","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/00000658-199910000-00002","article-title":"Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA","volume":"230","author":"Rosengart","year":"1999","journal-title":"Ann Surg"},{"issue":"9 Suppl","key":"10.1016\/j.athoracsur.2015.12.004_bib39","first-page":"I157","volume":"112","author":"Gy\u00f6ngy\u00f6si","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib40","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0003-4975(99)01102-9","article-title":"Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121","volume":"69","author":"Lee","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib41","series-title":"Cardiac surgery in the adult","first-page":"711","article-title":"Coronary artery reoperations","author":"Gonzalez-Stawinski","year":"2007"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/01.CIR.98.1.82","article-title":"Cell cycle progression: new therapeutic target for vascular proliferative disease","volume":"98","author":"Braun-Dullaeus","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib43","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1172\/JCI119288","article-title":"Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts","volume":"99","author":"Mann","year":"1997","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib44","doi-asserted-by":"crossref","first-page":"e73146","DOI":"10.1371\/journal.pone.0073146","article-title":"c-Myc is essential to prevent endothelial pro-inflammatory senescent phenotype","volume":"8","author":"Florea","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib45","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cardfail.2008.02.005","article-title":"Design of a phase 1\/2 trial of intracoronary administration of AAV1\/SERCA2a in patients with heart failure","volume":"14","author":"Hajjar","year":"2008","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib46","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jchf.2013.09.008","article-title":"Design of phase 2b trial of intracoronary administration of AAV1\/SERCA2a in patients with advanced heart failure: the CUPID2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b)","volume":"1","author":"Greenberg","year":"2014","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib47","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.ejcts.2009.01.044","article-title":"Modalities and future prospects of gene therapy in heart transplantation","volume":"35","author":"Vassalli","year":"2009","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib48","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1067\/mtc.2003.264","article-title":"Gene therapy in cardiac surgery: is there a role?","volume":"125","author":"Sellke","year":"2003","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1089\/hgtb.2012.105","article-title":"Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer","volume":"23","author":"Fang","year":"2012","journal-title":"Hum Gene Ther Methods"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib50","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.amjcard.2014.07.007","article-title":"Comparison of five-year outcome of coronary artery bypass grafting versus percutaneous coronary intervention in patients with left ventricular ejection fractions \u226450% versus >50% (from the CREDO-Kyoto PCI\/CABG Registry Cohort-2)","volume":"114","author":"Marui","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib51","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1056\/NEJMoa1100358","article-title":"Myocardial viability and survival in ischemic left ventricular dysfunction","volume":"364","author":"Bonow","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib52","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/gt.2012.36","article-title":"Prospects for gene transfer for clinical heart failure","volume":"19","author":"Tang","year":"2012","journal-title":"Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib53","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jtcvs.2014.05.070","article-title":"Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathy","volume":"148","author":"Katz","year":"2014","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/gt.2008.120","article-title":"Recirculating cardiac delivery of AAV2\/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals","volume":"15","author":"Byrne","year":"2008","journal-title":"Gene Ther"},{"key":"10.1016\/j.athoracsur.2015.12.004_bib55","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","article-title":"Coronary-artery bypass surgery in patients with left ventricular dysfunction","volume":"364","author":"Velazquez","year":"2011","journal-title":"N\u00a0Engl J Med"}],"container-title":["The Annals of Thoracic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349751501989X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000349751501989X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T03:36:16Z","timestamp":1757734576000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000349751501989X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S000349751501989X"],"URL":"https:\/\/doi.org\/10.1016\/j.athoracsur.2015.12.004","relation":{},"ISSN":["0003-4975"],"issn-type":[{"value":"0003-4975","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and Perspectives","name":"articletitle","label":"Article Title"},{"value":"The Annals of Thoracic Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athoracsur.2015.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The Society of Thoracic Surgeons Published by Elsevier","name":"copyright","label":"Copyright"}]}}